From: A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma
n
%
Gender
Male
31
73.8%
Female
11
26.2%
Age
≤ 50 years
20
47.6%
> 50 years
22
52.4%
Distance from anal verge
≤ 5 cm
27
64.3%
> 5 cm
15
35.7%
cT
T3
28
66.7%
T4
14
33.3%
cN
N0
5
11.9%
N1
N2
Total
42
100.0%